137 related articles for article (PubMed ID: 30357930)
1. Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers.
Zastrozhin MS; Sorokin AS; Agibalova TV; Grishina EA; Antonenko AР; Rozochkin IN; Duzhev DV; Skryabin VY; Galaktionova TE; Barna IV; Orlova AV; Aguzarov AD; Savchenko LM; Bryun EA; Sychev DA
Hum Psychopharmacol; 2018 Nov; 33(6):e2677. PubMed ID: 30357930
[TBL] [Abstract][Full Text] [Related]
2. Using a pharmacogenetic clinical decision support system to improve psychopharmacotherapy dosing in patients with affective disorders.
Zastrozhin M; Skryabin V; Sorokin A; Buzik O; Bedina I; Grishina E; Ryzhikova K; Shipitsyn V; Bryun E; Sychev D
Drug Metab Pers Ther; 2020 Sep; 35(4):. PubMed ID: 32870807
[TBL] [Abstract][Full Text] [Related]
3. Effects of CYP2C19*17 polymorphisms on the efficacy and safety of bromodigyrochlorophenylbenzodiazepine in patients with anxiety disorder and comorbid alcohol use disorder.
Zastrozhin MS; Antonenko AP; Nesterenko EV; Seyfullaeva LI; Mustafina VR; Esakova AP; Grishina EA; Sorokin AS; Skryabin VY; Savchenko LM; Bryun EA; Sychev DA
Drug Metab Pers Ther; 2018 Dec; 33(4):187-194. PubMed ID: 30325732
[TBL] [Abstract][Full Text] [Related]
4. Effects of
Zastrozhin MS; Skryabin VY; Torrado M; Petrovna A; Sorokin AS; Grishina EA; Ryzhikova KA; Bedina IA; Buzik OZ; Chumakov EM; Savchenko LM; Brun EA; Sychev DA
Pharmacogenomics; 2020 Jan; 21(2):111-123. PubMed ID: 31957548
[No Abstract] [Full Text] [Related]
5. How do CYP2C19*2 and CYP2C19*17 genetic polymorphisms affect the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome?
Skryabin VY; Zastrozhin MS; Torrado MV; Grishina EA; Ryzhikova KA; Shipitsyn VV; Galaktionova TE; Sorokin AS; Bryun EA; Sychev DA
Drug Metab Pers Ther; 2020 Mar; 35(1):. PubMed ID: 32134726
[TBL] [Abstract][Full Text] [Related]
6. Effects of plasma concentration of micro-RNA Mir-27b and CYP3A4*22 on equilibrium concentration of alprazolam in patients with anxiety disorders comorbid with alcohol use disorder.
Zastrozhin MS; Skryabin VY; Smirnov VV; Petukhov AE; Pankratenko EP; Zastrozhina AK; Grishina EA; Ryzhikova KA; Bure IV; Golovinskii PA; Koporov SG; Bryun EA; Sychev DA
Gene; 2020 May; 739():144513. PubMed ID: 32112986
[TBL] [Abstract][Full Text] [Related]
7. CYP3A subfamily activity affects the equilibrium concentration of Phenazepam
Zastrozhin MS; Skryabin VY; Sorokin AS; Petukhov AE; Smirnov VV; Pankratenko EP; Grishina EA; Ryzhikova KA; Panov AS; Savchenko LM; Bryun EA; Sychev DA
Pharmacogenomics; 2020 May; 21(7):449-457. PubMed ID: 32336193
[TBL] [Abstract][Full Text] [Related]
8. Role of CYP2C19 gene polymorphism in acute alcohol withdrawal treatment with loading dose of diazepam in a South Indian population.
Jose M; Mathaiyan J; Kattimani S; Adithan S; Chandrasekaran A
Eur J Clin Pharmacol; 2016 Jul; 72(7):807-12. PubMed ID: 27099220
[TBL] [Abstract][Full Text] [Related]
9. Systematic evaluation of commercial pharmacogenetic testing in psychiatry: a focus on CYP2D6 and CYP2C19 allele coverage and results reporting.
Bousman CA; Jaksa P; Pantelis C
Pharmacogenet Genomics; 2017 Nov; 27(11):387-393. PubMed ID: 28777243
[TBL] [Abstract][Full Text] [Related]
10. Using the CYP3A Activity Evaluation to Predict the Efficacy and Safety of Diazepam in Patients With Alcohol Withdrawal Syndrome.
Skryabin VY; Zastrozhin MS; Grishina EA; Ryzhikova KA; Shipitsyn VV; V Barna I; Galaktionova TE; Ivanov AV; Sorokin AS; Bryun EA; Sychev DA
J Pharm Pract; 2022 Aug; 35(4):518-523. PubMed ID: 33622083
[TBL] [Abstract][Full Text] [Related]
11. Effects of CYP2C19*17 genetic polymorphisms on plasma and saliva concentrations of diazepam in patients with alcohol withdrawal syndrome.
Skryabin VY; Zastrozhin M; Torrado M; Grishina E; Ryzhikova K; Shipitsyn V; Galaktionova T; Bryun E; Sychev D
Psychiatr Genet; 2022 Apr; 32(2):67-73. PubMed ID: 35001019
[TBL] [Abstract][Full Text] [Related]
12. Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility.
Bradley P; Shiekh M; Mehra V; Vrbicky K; Layle S; Olson MC; Maciel A; Cullors A; Garces JA; Lukowiak AA
J Psychiatr Res; 2018 Jan; 96():100-107. PubMed ID: 28992526
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia).
Fedorinov DS; Mirzaev KB; Ivashchenko DV; Temirbulatov II; Sychev DA; Maksimova NR; Chertovskih JV; Popova NV; Tayurskaya KS; Rudykh ZA
Drug Metab Pers Ther; 2018 Jun; 33(2):91-98. PubMed ID: 29738309
[TBL] [Abstract][Full Text] [Related]
14. Utilizing CIWA-Ar to assess use of benzodiazepines in patients vulnerable to alcohol withdrawal syndrome.
Nuss MA; Elnicki DM; Dunsworth TS; Makela EH
W V Med J; 2004; 100(1):21-5. PubMed ID: 15119493
[TBL] [Abstract][Full Text] [Related]
15. Gamma-hydroxybutyric acid (GHB) in the treatment of alcohol withdrawal syndrome: a randomized comparative study versus benzodiazepine.
Addolorato G; Balducci G; Capristo E; Attilia ML; Taggi F; Gasbarrini G; Ceccanti M
Alcohol Clin Exp Res; 1999 Oct; 23(10):1596-604. PubMed ID: 10549990
[TBL] [Abstract][Full Text] [Related]
16. Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial.
Reoux JP; Saxon AJ; Malte CA; Baer JS; Sloan KL
Alcohol Clin Exp Res; 2001 Sep; 25(9):1324-9. PubMed ID: 11584152
[TBL] [Abstract][Full Text] [Related]
17. Development and implementation of an alcohol withdrawal protocol using a 5-item scale, the Brief Alcohol Withdrawal Scale (BAWS).
Rastegar DA; Applewhite D; Alvanzo AAH; Welsh C; Niessen T; Chen ES
Subst Abus; 2017; 38(4):394-400. PubMed ID: 28699845
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of pregabalin in the treatment of alcohol withdrawal syndrome: a randomized placebo-controlled trial.
Förg A; Hein J; Volkmar K; Winter M; Richter C; Heinz A; Müller CA
Alcohol Alcohol; 2012; 47(2):149-55. PubMed ID: 22215002
[TBL] [Abstract][Full Text] [Related]
19. A Symptom-Triggered Benzodiazepine Protocol Utilizing SAS and CIWA-Ar Scoring for the Treatment of Alcohol Withdrawal Syndrome in the Critically Ill.
Sen S; Grgurich P; Tulolo A; Smith-Freedman A; Lei Y; Gray A; Dargin J
Ann Pharmacother; 2017 Feb; 51(2):101-110. PubMed ID: 27733668
[TBL] [Abstract][Full Text] [Related]
20. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Cavallari LH; Lee CR; Beitelshees AL; Cooper-DeHoff RM; Duarte JD; Voora D; Kimmel SE; McDonough CW; Gong Y; Dave CV; Pratt VM; Alestock TD; Anderson RD; Alsip J; Ardati AK; Brott BC; Brown L; Chumnumwat S; Clare-Salzler MJ; Coons JC; Denny JC; Dillon C; Elsey AR; Hamadeh IS; Harada S; Hillegass WB; Hines L; Horenstein RB; Howell LA; Jeng LJB; Kelemen MD; Lee YM; Magvanjav O; Montasser M; Nelson DR; Nutescu EA; Nwaba DC; Pakyz RE; Palmer K; Peterson JF; Pollin TI; Quinn AH; Robinson SW; Schub J; Skaar TC; Smith DM; Sriramoju VB; Starostik P; Stys TP; Stevenson JM; Varunok N; Vesely MR; Wake DT; Weck KE; Weitzel KW; Wilke RA; Willig J; Zhao RY; Kreutz RP; Stouffer GA; Empey PE; Limdi NA; Shuldiner AR; Winterstein AG; Johnson JA;
JACC Cardiovasc Interv; 2018 Jan; 11(2):181-191. PubMed ID: 29102571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
